2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

Anti fibrotic

" in MedChemExpress (MCE) Product Catalog:

115

Inhibitors & Agonists

15

Peptides

1

Inhibitory Antibodies

23

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15307
    Belumosudil
    Maximum Cited Publications
    34 Publications Verification

    KD025; SLx-2119

    		 ROCK Inflammation/Immunology Cancer
    Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
    Belumosudil
  • HY-12403
    Talfirastide
    Maximum Cited Publications
    17 Publications Verification

    TXA127; Angiotensin (1-7); Ang-(1-7)

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide
  • HY-N0664
    Aucubin
    5+ Cited Publications

    		 Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aucubin is an iridoid glycoside component that acn be found in E. ulmoides. Aucubin can cross the blood-brain barrier (BBB) and has anti-anxiety, antidepressive and anti-neuroinflammatory effects. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
    Aucubin
  • HY-P0256
    Apamin
    5+ Cited Publications

    Apamine

    		 Potassium Channel Neurological Disease Inflammation/Immunology
    Apamin (Apamine) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of Ca 2+-activated K + (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity .
    Apamin
  • HY-148808
    Zelasudil

    RXC007

    		 ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
    Zelasudil
  • HY-101737
    24-Norursodeoxycholic acid
    1 Publications Verification

    Norucholic acid; nor-UDCA

    		 Biochemical Assay Reagents Inflammation/Immunology
    24-norursodeoxycholic acid (Norucholic acid) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties.
    24-Norursodeoxycholic acid
  • HY-15307A
    Belumosudil mesylate
    Maximum Cited Publications
    34 Publications Verification

    KD025 mesylate; SLx-2119 mesylate

    		 ROCK Inflammation/Immunology
    Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .
    Belumosudil mesylate
  • HY-P0170
    TB500
    1 Publications Verification

    		 Drug Derivative Akt P2X Receptor Inflammation/Immunology
    TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation .
    TB500
  • HY-100113
    Buloxibutid
    5 Publications Verification

    AT2 receptor agonist C21

    		 Angiotensin Receptor p38 MAPK TGF-beta/Smad TGF-β Receptor MMP Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .
    Buloxibutid
  • HY-148087
    AZD5462
    1 Publications Verification

    		 RXFP Receptor Cardiovascular Disease
    AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties .
    AZD5462
  • HY-126397
    MnTBAP chloride
    5+ Cited Publications

    		 NF-κB Inflammation/Immunology
    MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .
    MnTBAP chloride
  • HY-136657
    SC-43
    5+ Cited Publications

    		 SHP1 Phosphatase STAT Apoptosis Cancer
    SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects .
    SC-43
  • HY-14928
    Lobeglitazone

    		PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .
    Lobeglitazone
  • HY-N1548
    Prunasin
    1 Publications Verification

    		 DNA/RNA Synthesis Inflammation/Immunology
    Prunasin is an orally active cyanogenic glucoside and the main metabolite of Amygdalin (HY-N0190). Prunasin can specifically inhibit rat DNA polymerase β (IC50: 98 μM). Prunasin has anti-inflammatory and anti-fibrotic activities. Prunasin can be used in the research of diseases such as liver fibrosis .
    Prunasin
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-N6985
    Baccatin III
    2 Publications Verification

    		 Others Cancer
    Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment .
    Baccatin III
  • HY-112606
    ML-290

    		RXFP Receptor Others
    ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
    ML-290
  • HY-100495
    FT011
    2 Publications Verification

    Asengeprast

    		 MMP Inflammation/Immunology
    FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis . FT011 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FT011
  • HY-P10728
    B7-33

    		RXFP Receptor ERK Cardiovascular Disease Inflammation/Immunology
    B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
    B7-33
  • HY-N0311
    Emodin-8-glucoside
    2 Publications Verification

    		 Aldose Reductase Topoisomerase SOD p38 MAPK Neurological Disease Inflammation/Immunology
    Emodin-8-glucoside is an anthraquinone derivative that can be isolated from Aloe vera. Emodin-8-glucoside is the inhibitor for MAPK with an inhibition constant of 430.14 pM. Emodin-8-glucoside exhibits moderate inhibitory activity against rat lens aldose reductase (ALAR) and topoisomerases II with IC50s of 14.4 μM and 66 μM. Emodin-8-glucoside exhibits antioxidant, anti-inflammatory and anti-fibrotic activities. Emodin-8-glucoside can cross the blood brain barrier .
    Emodin-8-glucoside
  • HY-130242
    PXS-5120A

    		Monoamine Oxidase Inflammation/Immunology
    PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of Lysyl Oxidase-like 2/3 (LOXL2/3) with anti-fibrotic activity. PXS-5120A is >300-fold selective for LOXL2 (Ki of 83 nM; pIC50 of 8.4) over LOXL (pIC50 of 5.8) .
    PXS-5120A
  • HY-A0060
    Malotilate

    NKK 105

    		 Lipoxygenase Cancer
    Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
    Malotilate
  • HY-18303
    AMG-47a
    3 Publications Verification

    		 Src VEGFR p38 MAPK JAK Inflammation/Immunology
    AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
    AMG-47a
  • HY-121246
    Fluorofenidone
    1 Publications Verification

    AKF-PD

    		 ACSL Family NF-κB ERK TGF-beta/Smad Inflammation/Immunology Cancer
    Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
    Fluorofenidone
  • HY-15183
    Collagen proline hydroxylase inhibitor

    		Collagen Cancer
    Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor, which can be used as an anti-fibrotic agent .
    Collagen proline hydroxylase inhibitor
  • HY-100775
    Fezagepras sodium
    1 Publications Verification

    Setogepram sodium; PBI-4050 sodium

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras sodium decreases renal, liver and pancreatic fibrosis . Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
    Fezagepras sodium
  • HY-100775A
    Fezagepras
    1 Publications Verification

    Setogepram; PBI-4050

    		 Free Fatty Acid Receptor GPR84 Metabolic Disease Inflammation/Immunology
    Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 . Fezagepras decreases renal, liver and pancreatic fibrosis . Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .
    Fezagepras
  • HY-124646
    KIRA-7

    		IRE1 Inflammation/Immunology
    KIRA-7, an imidazopyrazine compound, binds the IRE1α kinase (IC50 of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect .
    KIRA-7
  • HY-N4107
    Phyllanthin
    1 Publications Verification

    		 TGF-beta/Smad Infection Inflammation/Immunology Cancer
    Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
    Phyllanthin
  • HY-132850
    Dazcapistat

    BLD-2660

    		 Proteasome Interleukin Related Infection Inflammation/Immunology
    Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis .
    Dazcapistat
  • HY-12403A
    Talfirastide acetate
    Maximum Cited Publications
    17 Publications Verification

    TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
    Talfirastide acetate
  • HY-163536
    TGF-β1/Smad3-IN-1

    		TGF-beta/Smad Inflammation/Immunology
    TGF-β1/Smad3-IN-1 (Compound 5aa) is an inhibitor of the TGF-β1/Smad3 signaling pathway(IC50=1.07 μM). TGF-β1/Smad3-IN-1 possesses antifibrotic activity and oral potency .
    TGF-β1/Smad3-IN-1
  • HY-160851
    GDC-3280

    AK3287; AKEX0011

    		 ASK1 p38 MAPK Inflammation/Immunology
    GDC-3280 (AK3287; AKEX0011) is an orally active compound based on Pirfenidone (HY-B0673)'s phenyl pyridone scaffold. GDC-3280 alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 MAPK pathway and regulating macrophage polarization. GDC-3280 exhibits anti-inflammatory and anti-fibrotic effects .
    GDC-3280
  • HY-14928A
    Lobeglitazone sulfate

    		PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .
    Lobeglitazone sulfate
  • HY-162334
    HYOU1-IN-1

    		HSP Inflammation/Immunology Cancer
    HYOU1-IN-1 (Compound 33) is an inhibitor of hypoxia-upregulated protein 1 (HYOU1) with anti-inflammatory activity. HYOU1-IN-1 can be used in research on the regulation of fibroblast activation, chronic inflammation, and fibrotic diseases .
    HYOU1-IN-1
  • HY-107802
    Breviscapine
    2 Publications Verification

    Breviscapinun

    		 NF-κB Interleukin Related TGF-beta/Smad Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Breviscapine (Breviscapinun) is a flavonoid compound with antioxidant, anti-inflammatory, anti-fibrotic, and neuroprotective activities. Breviscapine ameliorates cerebral ischemia/reperfusion injury and vascular dementia, and inhibits the formation of postoperative abdominal adhesions. The mechanism of action of Breviscapine involves the regulation of oxidative stress, inflammatory cytokines, signaling pathways such as TGF-β/Smad, and cellular calcium overload. Breviscapine is used for research on diseases including cardiovascular and cerebrovascular diseases .
    Breviscapine
  • HY-N1508
    Ecliptasaponin A

    		MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .
    Ecliptasaponin A
  • HY-170538
    SNT-5382

    		Lysyl Oxidase Cytochrome P450 Cardiovascular Disease Metabolic Disease
    SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis .
    SNT-5382
  • HY-120268A
    SLM6031434 hydrochloride

    		SphK Inflammation/Immunology
    SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
    SLM6031434 hydrochloride
  • HY-N0664R
    Aucubin (Standard)

    		Reference Standards Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    Aucubin (Standard) is the analytical standard of Aucubin. This product is intended for research and analytical applications. Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects .
    Aucubin (Standard)
  • HY-P10414A
    Klotho-derived peptide 1 hydrochloride

    KP1 (human) hydrochloride

    		 TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1 hydrochloride
  • HY-113604
    Pentabromopseudilin

    		TGF-β Receptor Cancer
    Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour and phytotoxic activities. PBrP is a reversible and allosteric inhibitor of myosin Va (MyoVa). PBrP also is a potent inhibitor of transforming growth factor-β (TGF-β) activity. PBrP can be used for the research of fibrotic diseases and cancer .
    Pentabromopseudilin
  • HY-N0671R
    Rhapontin (Standard)
    2 Publications Verification

    Rhaponiticin (Standard)

    		 Reference Standards Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin (Standard)
  • HY-146434
    TGFβ-IN-2
    1 Publications Verification

    		 TGF-beta/Smad Inflammation/Immunology
    TGFβ-IN-2 is an orally active TGF-β inhibitor. TGFβ-IN-2 suppresses the TGF-β-induced protein expression of COL1A1, α-SMA, and p-Smad3 in vitro. TGFβ-IN-2 demonstrates excellent anti-fibrotic efficacy in Bleomycin (HY-108345)-induced pulmonary fibrosis model. TGFβ-IN-2 can be used for the study of pulmonary fibrosis .
    TGFβ-IN-2
  • HY-156119
    MLKL-IN-6

    		Mixed Lineage Kinase Necroptosis Metabolic Disease Cancer
    MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .
    MLKL-IN-6
  • HY-N6928
    Mogroside III-E

    		Toll-like Receptor (TLR) Metabolic Disease Cancer
    Mogroside III-E is a cucurbitane-type compound isolated from Siraitia grosvenorii, inhibits NO release, with anti-fibrotic activity .
    Mogroside III-E
  • HY-P10414
    Klotho-derived peptide 1

    KP1 (human)

    		 TGF-beta/Smad p38 MAPK Inflammation/Immunology
    Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .
    Klotho-derived peptide 1
  • HY-P3618
    Cortistatin-29 (reduced)

    		Somatostatin Receptor Neurological Disease Inflammation/Immunology
    Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .
    Cortistatin-29 (reduced)
  • HY-176274
    FASN/SCD-IN-1

    		Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase Metabolic Disease Inflammation/Immunology
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .
    FASN/SCD-IN-1
  • HY-120268
    SLM6031434

    		SphK Inflammation/Immunology
    SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .
    SLM6031434

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: